Abstract: A slow-light generating optical device (1) is disclosed. The optical device comprises a planar waveguide (2), and the planar waveguide comprises: a longitudinal extending guiding region (4) with a first side (6) and a second side (8), a first nanostructure (7) arranged on the first side (6) of the guiding region (4), and a second nanostructure (9) arranged on the second side (7) of the guiding region (4). The planar waveguide (2) includes a first longitudinal region where the first nanostructure (7) and the second structure (9) are arranged substantially glide-plane symmetric about the guiding region (4) of the planar waveguide, and the first and the second nanostructures (7, 9) are designed so that the planar waveguide has a band structure and is adapted to guide a forward propagating mode and a backward propagating mode possessing energy bands, which individually are non-degenerate and mutually degenerate, and which intersect each other and form a Dirac point at a Brillouin zone edge.

Abstract: An optical device comprising a planar waveguide and a quantum emitter is presented. The planar waveguide comprises a longitudinal extending guiding region with a first side and a second side. A first nanostructure is arranged on the first side of the guiding region, and a second nanostructure arranged on the second side of the guiding region. The planar waveguide includes a first longitudinal region where the first nanostructure and the second structure are arranged substantially glide-plane symmetric about the guiding region of the planar waveguide, and the quantum emitter is coupled to the first longitudinal region of the planar waveguide.

Abstract: The present invention discloses peptide fragments derived from neuropeptide Y (NPY), which are capable of selective binding to the neural cell adhesion molecule (NCAM) and inducing neuroplastic and neuroprotective effects, and the use of said peptide fragments as neuritogenic agents for treatment of pathological conditions in which neuroprotection and neuroplastic changes are desired, such as brain and retina disorders.

Abstract: The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analog comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analog thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analog thereof, wherein an amino-terminal residue of the peptide is N-alkylated.

Abstract: Solvent consumption in supercritical ethanol, propanol or butanol treatment of either refined pre-extracted lignin or comparatively impure lignin-rich solid residual from hydrothermally pretreated lignocellulosic biomass can be minimized by conducting the reaction at very high loading of lignin to solvent. Comparatively impure, crude lignin-rich solid residual can be directly converted by supercritical alcohol treatment to significantly diesel-soluble lignin oil without requirement for pre-extraction or pre-solubilisation of lignin or for added reaction promoters such as catalysts, hydrogen donor co-solvents, acids, based or H2 gas. O:C ratio of product oil can readily be obtained using crude lignin residual in such a process at levels 0.20 or lower.

Abstract: The present invention relates to methods for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing non-fat energy uptake in the gastrointestinal tract of a mammal in order to prevent a positive non-fat energy balance, weight gain, overweight and obesity, and to induce a negative non-fat energy balance and weight loss in subjects who wish to reduce their body weight. In particular, feed, food and/or beverages and dietary supplements of the present invention comprises mucilage such as flax seed mucilage and/or one or more active compounds of mucilage useful for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing the digestibility of non-fat energy in the gastrointestinal tract of a mammal.

Abstract: An optical device comprising a single-photon device, which is coupled to a planar waveguide is described. The planar waveguide comprises a nanostructured section, which includes a longitudinal extending guiding region with a first side and a second side, a first nanostructure arranged on the first side of the guiding region, and a second nanostructure arranged on the second side of the guiding region. The nanostructured section comprises a slow-mode section, in which the single-photon device is positioned or embedded, and in which the first nanostructure and second nanostructure suppress spontaneous emission into other modes. The planar waveguide further comprises a fiber coupler for coupling light out of the planar waveguide and into an optical fiber, the fiber coupler preferably being adapted to match a field profile of an optical fiber.

Abstract: The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.

Abstract: An optical device comprising a single-photon device, which is coupled to a planar waveguide is described. The planar waveguide comprises a nanostructured section, which includes a longitudinal extending guiding region with a first side and a second side, a first nanostructure arranged on the first side of the guiding region, and a second nanostructure arranged on the second side of the guiding region. The nanostructured section comprises a slow-mode section, in which the single-photon device is positioned or embedded, and in which the first nanostructure and second nanostructure suppress spontaneous emission into other modes. The planar waveguide further comprises a fibre coupler for coupling light out of the planar waveguide and into an optical fibre, the fibre coupler preferably being adapted to match a field profile of an optical fibre.

Abstract: The present invention relates to methods for preparing patchoulol, ?-santalene, and sclareol in transgenic moss cells that include heterologous nucleic acid molecules encoding a polypeptide or synthase capable of using FPP or GGPP as a substrate. Methods for producing the transgenic moss cell, as well as the transgenic moss cell itself are also disclosed.

Abstract: A method of performing eye gaze tracking of at least one eye of a user, by determining the position of the center of the eye, said method comprising the steps of: detecting the position of at least three reflections on said eye, transforming said positions to spanning a normalized coordinate system spanning a frame of reference, detecting the position of said center of the eye relative to the position of said reflections and transforming this position to said normalized coordinate system, tracking the eye gaze by tracking the movement of said eye in said normalized coordinate system. Thereby calibration of a camera, such as knowledge of the exact position and zoom level of the camera, is avoided. Further, it is not necessary to know the position of light sources. This results in a much more flexible and user friendly system.

Abstract: MRSA CC398 is a clone of S. aureus that has recently emerged in pigs and other domestic animals worldwide. As any other MRSA, the clone displays high levels of antibiotic resistance and poses a serious threat to human health because of the risk of antibiotic treatment failure in human patients. We developed a new diagnostic test for identification of MRSA CC398 using a single one-step PCR that is very easily performed within a few hours. The test is based on the principle that clonal differences within S. aureus are reflected in the sequence of a gene (sau1hsdS1) located on the chromosome of this bacterial species. Accordingly, such a gene represents an optimal target for S. aureus and MRSA identification at the clone level. The test includes detection of the gene conferring methicillin resistance (mecA), therefore allowing rapid discrimination between methicillin-susceptible and methicillin-resistant variants of the clone.

Abstract: The present invention discloses peptide fragments derived from neuropeptide Y (NPY), which are capable of selective binding to the neural cell adhesion molecule (NCAM) and inducing neuroplastic and neuroprotective effects, and the use of said peptide fragments as neuritogenic agents for treatment of pathological conditions in which neuroprotection and neuroplastic changes are desired, such as brain and retina disorders.

Abstract: The present disclosure embraces Kalanchoë interspecific hybrid plants, and considers rol transformation in Kalanchoë species and hybrids. Disclosed herein are methodology and the like for producing rol-transformed Kalanchoë interspecific hybrid plants, as well as resultant rol-transformed Kalanchoë interspecific hybrid plants with novel phenotypes.

Abstract: The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, wherein an amino-terminal residue of the peptide is N-alkylated.

Abstract: The invention provides novel potent inhibitors of the ternary protein complex of nNOS, PSD-95, and the NMDA receptor and pharmaceutical compositions comprising the inhibitors for prophylaxis and/or treatment of excitotoxic-related disease and chronic pain conditions in a subject. The inhibitors are dimeric PSD-95 inhibitors comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, wherein the first and the second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence YTXV (SEQ ID NO: 5) or YSXV (SEQ ID NO: 6), wherein a. Y is selected from among E, Q, and A, or an analogue thereof, and b. X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, and wherein a Cell Penetrating Peptide (CPP) is linked to the linker or to an amino acid side chain of the first and second peptide or peptide analogue. The linker can be a PEG or NPEG linker.

Abstract: The present invention relates to methods for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing non-fat energy uptake in the gastrointestinal tract of a mammal in order to prevent a positive non-fat energy balance, weight gain, overweight and obesity, and to induce a negative non-fat energy balance and weight loss in subjects who wish to reduce their body weight. In particular, feed, food and/or beverages and dietary supplements of the present invention comprises mucilage such as flax seed mucilage and/or one or more active compounds of mucilage useful for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing the digestibility of non-fat energy in the gastrointestinal tract of a mammal.

Abstract: The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.

Abstract: The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement ac

Abstract: The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.